702 related articles for article (PubMed ID: 18757334)
21. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Ishii D; Natsume A; Wakabayashi T; Hatano H; Asano Y; Takeuchi H; Shimato S; Ito M; Fujii M; Yoshida J
Neurol Med Chir (Tokyo); 2007 Aug; 47(8):341-9; discussion 350. PubMed ID: 17721049
[TBL] [Abstract][Full Text] [Related]
22. Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres.
Sciuscio D; Diserens AC; van Dommelen K; Martinet D; Jones G; Janzer RC; Pollo C; Hamou MF; Kaina B; Stupp R; Levivier M; Hegi ME
Clin Cancer Res; 2011 Jan; 17(2):255-66. PubMed ID: 21097691
[TBL] [Abstract][Full Text] [Related]
23. In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing.
Kreth S; Limbeck E; Hinske LC; Schütz SV; Thon N; Hoefig K; Egensperger R; Kreth FW
Acta Neuropathol; 2013 May; 125(5):671-81. PubMed ID: 23340988
[TBL] [Abstract][Full Text] [Related]
24. Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma.
Seystahl K; Hentschel B; Loew S; Gramatzki D; Felsberg J; Herrlinger U; Westphal M; Schackert G; Thon N; Tatagiba M; Pietsch T; Reifenberger G; Löffler M; Wick W; Weller M;
J Cancer Res Clin Oncol; 2020 Mar; 146(3):659-670. PubMed ID: 31754832
[TBL] [Abstract][Full Text] [Related]
25. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
[TBL] [Abstract][Full Text] [Related]
26. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
Brandes AA; Franceschi E; Tosoni A; Benevento F; Scopece L; Mazzocchi V; Bacci A; Agati R; Calbucci F; Ermani M
Cancer; 2009 Aug; 115(15):3512-8. PubMed ID: 19514084
[TBL] [Abstract][Full Text] [Related]
27. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
28. MGMT Epigenetics: The Influence of Gene Body Methylation and Other Insights Derived from Integrated Methylomic, Transcriptomic, and Chromatin Analyses in Various Cancer Types.
Bacolod MD; Barany F
Curr Cancer Drug Targets; 2021; 21(4):360-374. PubMed ID: 33535955
[TBL] [Abstract][Full Text] [Related]
29. Total DNA methylation profile in assessing the MGMT gene promoter status in malignant gliomas.
Petrova EI; Galstyan SA; Telysheva EN; Ryzhova MV
Zh Vopr Neirokhir Im N N Burdenko; 2023; 87(6):52-58. PubMed ID: 38054227
[TBL] [Abstract][Full Text] [Related]
30. O
Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
[TBL] [Abstract][Full Text] [Related]
31. O
Yu W; Zhang L; Wei Q; Shao A
Front Oncol; 2019; 9():1547. PubMed ID: 32010632
[TBL] [Abstract][Full Text] [Related]
32. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
33. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
Brandes AA; Tosoni A; Cavallo G; Reni M; Franceschi E; Bonaldi L; Bertorelle R; Gardiman M; Ghimenton C; Iuzzolino P; Pession A; Blatt V; Ermani M;
J Clin Oncol; 2006 Oct; 24(29):4746-53. PubMed ID: 16954518
[TBL] [Abstract][Full Text] [Related]
34. O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems.
Silber JR; Bobola MS; Blank A; Chamberlain MC
Biochim Biophys Acta; 2012 Aug; 1826(1):71-82. PubMed ID: 22244911
[TBL] [Abstract][Full Text] [Related]
35. Transcriptional control of O
Happold C; Stojcheva N; Silginer M; Weiss T; Roth P; Reifenberger G; Weller M
J Neurochem; 2018 Mar; 144(6):780-790. PubMed ID: 29480969
[TBL] [Abstract][Full Text] [Related]
36. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide.
Natsume A; Ishii D; Wakabayashi T; Tsuno T; Hatano H; Mizuno M; Yoshida J
Cancer Res; 2005 Sep; 65(17):7573-9. PubMed ID: 16140920
[TBL] [Abstract][Full Text] [Related]
37. Post-transcriptional regulation of O(6)-methylguanine-DNA methyltransferase MGMT in glioblastomas.
Ramakrishnan V; Kushwaha D; Koay DC; Reddy H; Mao Y; Zhou L; Ng K; Zinn P; Carter B; Chen CC
Cancer Biomark; 2011-2012; 10(3-4):185-93. PubMed ID: 22674304
[TBL] [Abstract][Full Text] [Related]
38. O6 -methylguanine DNA methyltransferase gene promoter methylation in high-grade gliomas: a review of current status.
Suri V; Jha P; Sharma MC; Sarkar C
Neurol India; 2011; 59(2):229-35. PubMed ID: 21483124
[TBL] [Abstract][Full Text] [Related]
39. MGMT promoter methylation in malignant gliomas.
Riemenschneider MJ; Hegi ME; Reifenberger G
Target Oncol; 2010 Sep; 5(3):161-5. PubMed ID: 20725792
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]